Fig. 8: A proposed model showing a novel therapeutic strategy for HNSCC patients by using a combination of LSD1 inhibition and PD-1 blockade. | Cell Death & Disease

Fig. 8: A proposed model showing a novel therapeutic strategy for HNSCC patients by using a combination of LSD1 inhibition and PD-1 blockade.

From: Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade

Fig. 8: A proposed model showing a novel therapeutic strategy for HNSCC patients by using a combination of LSD1 inhibition and PD-1 blockade.The alternative text for this image may have been generated using AI.

High expression of LSD1 promotes the CSC properties by regulating Bmi-1 expression. Inhibition of LSD1 induces the upregulation of PDL1 levels and promotes tumor immune evasion. Combination of LSD1 inhibitor and anti-PD-1 monoclonal antibody can overcome tumor immune evasion and greatly inhibit tumor growth, which providing a novel and promising combined strategy for the treatment of HNSCC.

Back to article page